Anemia News and Research

RSS
Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.
Gamma interferon wakes-up sleeping stem cells to produce immune system cells to fight invading bacteria

Gamma interferon wakes-up sleeping stem cells to produce immune system cells to fight invading bacteria

Researchers validate effectiveness of genome sequencing process for hereditary genetic diseases

Researchers validate effectiveness of genome sequencing process for hereditary genetic diseases

Aeterna Zentaris reports final results on clinical activity of perifosine for metastatic colorectal cancer

Aeterna Zentaris reports final results on clinical activity of perifosine for metastatic colorectal cancer

Interim results from PROPEL study of RG7128 submitted as abstract to AASLD for Annual Liver Meeting

Interim results from PROPEL study of RG7128 submitted as abstract to AASLD for Annual Liver Meeting

S*BIO completes enrollment in SB1518 JAK2 inhibitor Phase 2 clinical trials for myelofibrosis

S*BIO completes enrollment in SB1518 JAK2 inhibitor Phase 2 clinical trials for myelofibrosis

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

Multiple presentations on nab-driven chemotherapy at 46th ASCO

Multiple presentations on nab-driven chemotherapy at 46th ASCO

Clinical trials of four investigational compounds in solid tumors presented at ASCO Annual Meeting

Clinical trials of four investigational compounds in solid tumors presented at ASCO Annual Meeting

CMAJ to publish comprehensive new guidelines on immigrant health

CMAJ to publish comprehensive new guidelines on immigrant health

U.S. Court issues claim construction order in patent infringement litigation between Cubist and Teva

U.S. Court issues claim construction order in patent infringement litigation between Cubist and Teva

Scientists combine two agents to treat patients with multiple myeloma

Scientists combine two agents to treat patients with multiple myeloma

Phase 2 Study: NKTR-102 holds great therapeutic potential for women with platinum-resistant/refractory ovarian cancer

Phase 2 Study: NKTR-102 holds great therapeutic potential for women with platinum-resistant/refractory ovarian cancer

Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO

Findings from Abraxis BioScience's phase 3 ABRAXANE trial in patients with NSCLC presented at ASCO

GTx presents quality of life results from Ostarine Phase IIb study in cancer cachexia patients at ASCO 2010

GTx presents quality of life results from Ostarine Phase IIb study in cancer cachexia patients at ASCO 2010

Hormone involved in iron metabolism can save mice from deadly acute inflammation: Scientists

Hormone involved in iron metabolism can save mice from deadly acute inflammation: Scientists

Form of epigenetics may play role in pulmonary arterial hypertension: Researchers

Form of epigenetics may play role in pulmonary arterial hypertension: Researchers

Researchers present data from Phase II study of lenalidomide in patients with untreated CLL at ASCO

Researchers present data from Phase II study of lenalidomide in patients with untreated CLL at ASCO

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations

Millennium reports on data of VELCADE for multiple myeloma from 2010 ASCO oral presentations

Allos Therapeutics reports data from PROPEL trial of FOLOTYN in patients with PTCL

Allos Therapeutics reports data from PROPEL trial of FOLOTYN in patients with PTCL

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.